Epidemiology and Cost of Patients with Cancer in Iran: 2018

• DOI: 10.30476/mejc.2019.83412.1162
• Publication Date: 2019-10-01
• Authors: Elahe Askarzade; Amin Adel; Hossein Ebrahimipour; Shapour Badiee Aval; Elahe Pourahmadi; Akbar Javan Biparva
• Keywords: Direct and indirect costs; Epidemiology; cancer; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282

Background: Third leading cause of mortality in the world is cancer, with more than 12 million new cases and nearly 7.6 deaths 2007. The time estimation healthcare costs patients cancer an important component developing national programs policies cancer. present study aimed to investigate epidemiology hospitalization who were admitted a regional referral center eastern Iran. Methods: research was descriptive had cross-sectional population-based design. It conducted on all Iran 2018. files hospitalized disease codes C0 D48/9 for treatment 2018 those discharged, extracted classified based international ICD10. Costs consisted four categories including direct patients, admission due outpatient costs, indirect costs. Statistical data analysis done by using criteria such as frequency, mean, standard deviation through STATA Version 11. Results: During study, 1467 referred Omid Hospital Mashhad. Among them, 49.9% males 50.1% females. 183 age range 56-60 years. highest prevalence related gastrointestinal organs (36%), hospital cost belonged cancers involving bone, cartilage joints (51.855 USD). total treating 1074990 USD average 73278 per patient. Hoteling portion 28% comprised cost. patients’ share out pocket payment 7% governmental 6%. paid insurance companies (87%). Discussion: results indicated that bore high during their treatment; hence, reducing these are needed. increasing number requires active participation responsible organizations along continuing financial support institutions banks or charities development appropriate government supporting patients.